238. ビタミンＤ抵抗性くる病/骨軟化症 Vitamin D-resistant rickets Clinical trials / Disease details
臨床試験数 : 28 / 薬物数 : 20 - (DrugBank : 9) / 標的遺伝子数 : 3 - 標的パスウェイ数 : 16
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | JPRN-JapicCTI-101332 | 01/9/2010 | 02/11/2010 | Therapeutic use of Z-521 | Therapeutic use of oral sodium phosphate (Z-521) in primary hypophosphatemic rickets (familial rickets, X-linked hypophosphatemia, vitamin D-resistant rickets) | primary hypophosphatemic rickets | Intervention name : Z-521 Dosage And administration of the intervention : 300-3000mg inorganic phosphorus is orally administered in 3 or 4 times per day | Zeria Pharmaceutical Co., Ltd. | NULL | 1 | 14 | BOTH | 10 | Phase 3 | NULL | |
| 2 | NCT01237288 (ClinicalTrials.gov) | September 2010 | 7/11/2010 | Therapeutic Use of Oral Sodium Phosphate (Z-521) in Primary Hypophosphatemic Rickets | Therapeutic Use of Oral Sodium Phosphate (Z-521) in Primary Hypophosphatemic Rickets | Primary Hypophosphatemic Rickets | Drug: Z-521 | Zeria Pharmaceutical | NULL | Completed | 1 Year | 14 Years | Both | 16 | Phase 3 | Japan |